PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN.
View/ Open
Date
2017-01-01Author
Gupta, A
Anjomani-Virmouni, S
Koundouros, N
Poulogiannis, G
Type
Journal Article
Metadata
Show full item recordAbstract
Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)-which is genetically linked to PD-promotes cancer progression via redox-mediated inactivation of phosphatase and tensin homolog (PTEN) by S-nitrosylation.
Collections
Research team
Signalling & Cancer Metabolism
Language
eng
Date accepted
2017-05-09
License start date
2017-01
Citation
Molecular & cellular oncology, 2017, 4 (6), pp. e1329692 - ?
Publisher
TAYLOR & FRANCIS INC